Zymeworks BC Inc [NASDAQ: ZYME] stock went on a downward path that fall over -0.20% on Friday, amounting to a one-week price decrease of less than -1.92%.
Over the last 12 months, ZYME stock rose by 1.16%. The one-year Zymeworks BC Inc stock forecast points to a potential upside of 35.94. The average equity rating for ZYME stock is currently 1.44, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $1.12 billion, with 74.85 million shares outstanding and 72.94 million shares in the current float. Compared to the average trading volume of 456.81K shares, ZYME stock reached a trading volume of 314209 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Zymeworks BC Inc [ZYME]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ZYME shares is $23.12 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ZYME stock is a recommendation set at 1.44. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
TD Cowen have made an estimate for Zymeworks BC Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on May 20, 2025. The new note on the price target was released on December 16, 2024, representing the official price target for Zymeworks BC Inc stock. Previously, the target price had yet another raise from $10 to $25, while Leerink Partners kept a Outperform rating on ZYME stock.
The Price to Book ratio for the last quarter was 3.34, with the Price to Cash per share for the same quarter was set at 3.72.
ZYME Stock Performance Analysis:
Zymeworks BC Inc [ZYME] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -1.92. With this latest performance, ZYME shares gained by 17.91% in over the last four-week period, additionally plugging by 10.52% over the last 6 months – not to mention a rise of 1.16% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ZYME stock in for the last two-week period is set at 62.78, with the RSI for the last a single of trading hit 0.57, and the three-weeks RSI is set at 0.59 for Zymeworks BC Inc [ZYME]. The present Moving Average for the last 50 days of trading for this stock 13.45, while it was recorded at 14.80 for the last single week of trading, and 13.22 for the last 200 days.
Insight into Zymeworks BC Inc Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and Zymeworks BC Inc [ZYME] shares currently have an operating margin of -67.32% and a Gross Margin at 89.52%. Zymeworks BC Inc’s Net Margin is presently recorded at -59.96%.
Zymeworks BC Inc (ZYME) Capital Structure & Debt Analysis
According to recent financial data for Zymeworks BC Inc. ( ZYME), the Return on Equity (ROE) stands at -19.89%, highlighting a negative impact on investor capital. The Return on Assets (ROA) is -15.95%, reflecting the company’s efficiency in generating profits from its assets. Additionally, Zymeworks BC Inc’s Return on Invested Capital (ROIC) is -21.07%, showcasing its effectiveness in deploying capital for earnings.
Zymeworks BC Inc (ZYME) Efficiency & Liquidity Metrics
Based on Zymeworks BC Inc’s (ZYME) latest financial statements, the Debt-to-Equity Ratio is 0.06%, indicating its reliance on debt financing relative to shareholder equity.
Zymeworks BC Inc (ZYME) Efficiency & Liquidity Metrics
From an operational efficiency perspective, Zymeworks BC Inc. (ZYME) effectively leverages its workforce, generating an average of -$257622.38 per employee. The company’s liquidity position is robust, with a Current Ratio of 7.69% and a Quick Ratio of 7.69%, indicating strong ability to cover short-term liabilities.
ZYME Stock EPS
With the latest financial reports released by the company, Zymeworks BC Inc posted -0.39/share EPS, while the average EPS was predicted by analysts to be reported at -0.41/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 0.02. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ZYME. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Zymeworks BC Inc go to -2.46%.
Zymeworks BC Inc [ZYME] Institutonal Ownership Details
There are presently around $101.50%, or 102.32%% of ZYME stock, in the hands of institutional investors. The top three institutional holders of ZYME stocks are: ECOR1 CAPITAL, LLC with ownership of 13.44 million shares, which is approximately 17.59%. BVF INC/IL, holding 5.87 million shares of the stock with an approximate value of $$49.95 million in ZYME stocks shares; and BVF INC/IL, currently with $$44.35 million in ZYME stock with ownership which is approximately 6.8214%.
